Ocular Therapeutix Inc. (OCUL)
7.88
-0.24 (-2.96%)
At close: Jan 14, 2025, 3:59 PM
7.93
0.63%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 7.07 |
| Market Cap | 1.24B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.29 |
| PE Ratio (ttm) | -6.11 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 8.87 |
| Volume | 1,172,316 |
| Avg. Volume (20D) | 935,081 |
| Open | 8.25 |
| Previous Close | 8.12 |
| Day's Range | 7.70 - 8.43 |
| 52-Week Range | 3.76 - 11.78 |
| Beta | undefined |
About OCUL
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammati...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 25, 2014
Employees 267
Stock Exchange NASDAQ
Ticker Symbol OCUL
Website https://www.ocutx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 90.36% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Ocular Therapeutix Inc. is scheduled to release its earnings on Mar 10, 2025,
during market hours.
Analysts project revenue of $17.75M, reflecting a 19.92% YoY growth and earnings per share of -0.22, making a -37.14% decrease YoY.
Analysts project revenue of $17.75M, reflecting a 19.92% YoY growth and earnings per share of -0.22, making a -37.14% decrease YoY.
3 months ago ·
Source
+12.12%
Ocular Therapeutix shares are trading higher after...
Unlock content with
Pro Subscription
6 months ago ·
Source
Ocular Therapeutics shares are trading higher after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $7 to $11.
